Medindia

X

Study Evaluating Clinical Performance of Cervista(R) HPV HR Presented at AOGIN

Tuesday, March 30, 2010 Drug News J E 4
Advertisement


BEDFORD, Mass., March 29 Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that interim data from the first large-scale independent evaluation of clinical performance of Cervista® HPV HR compared to Hybrid Capture 2 (hc2), were presented at the 4th Biennial Meeting of AOGIN (Asia-Oceanic Research Organization in Genital Infection and Neoplasia) in New Delhi, India on March 26-28, 2010. Cervista HPV HR is a diagnostic test for the detection of 14 high-risk human papillomavirus (HPV) types.

The study, SHENCCAST II, is a major cervical cancer screening trial including more than 10,000 women that is being conducted in China to evaluate the performance of HPV assays, among other endpoints. A preliminary analysis of data from 5,043 patients showed the Cervista HPV HR test performed as follows: Overall HPV positivity for this cohort was 12.2 percent for the Cervista HPV HR test and 14.6 percent with the hc2 test.

For histologically confirmed CIN 2 or more severe lesions, the Cervista HPV HR test showed a sensitivity of 90.7 percent and a specificity of 90.2 percent. For the hc2 test, sensitivity and specificity were 94.7 percent and 87.9 percent, respectively. While the Cervista HPV HR test demonstrated improved specificity and the hc2 test yielded higher sensitivity, a statistical analysis of overall test accuracy that plots sensitivity and specificity found the two methods were clinically equivalent (area under the ROC curves).

"These data further validate use of the Cervista HPV HR test as a viable method for identifying patients at risk of developing or harboring cervical neoplasia," said Jerome Belinson, MD, Professor of Surgery, Section of Gynecologic Oncology at the Cleveland Clinic and President of Preventive Oncology International. "It's the combination of sensitivity and specificity that best describes a test's diagnostic value. Our analysis clearly showed that both of these methods performed well and with similar accuracy."

"Hologic brought the Cervista HPV HR test to market to offer clinicians and labs specific advantages in HPV testing that were not offered with the competitive product, including an internal control to guard against false negatives, a lower required sample size and various workflow advantages for labs," said Edward Evantash, MD, Medical Director and Vice President of Medical Affairs at Hologic. "We are encouraged by the real-world clinical performance of Cervista HPV HR. Cervical cancer is the most common preventable cancer among women. Through both Cervista and our ThinPrep Pap Test, we are committed to continuing to advance the science and practice of preventing cervical cancer."(1)

About the Hologic Cervista® HPV Tests

The Cervista HPV HR and Cervista HPV 16/18 diagnostic tests are based on Invader® chemistry, a patented technology owned by Hologic and well established in other areas of molecular testing. Both tests are approved for use utilizing the sample collected with the ThinPrep® Pap Test, offering additional convenience for the healthcare provider.

Approved by the U.S. Food and Drug (FDA) Administration in March 2009, Cervista is the first new HPV assay in over a decade. It is the only FDA-approved test to feature an internal control, which allows confidence that a negative result is not the result of an insufficient sample. In addition, Cervista requires a sample size that is half that of the older competitor's test, which should result in fewer patient call backs. The assay also reduces lab processing time while providing some additional workflow advantages.

The Cervista HPV HR test screens for 14 of the most common disease-causing strains of HPV. The Cervista 16/18 test is the only HPV test available to diagnose for strains 16 and 18, which account for more than 70 percent of all cervical cancers.

About Human Papillomavirus and Cervical Cancer

HPV is the most common sexually-transmitted disease (STD) in the United States and is recognized as the cause of most cervical cancers. To help prevent the onset of disease, the American College of Obstetrics and Gynecology (ACOG) suggests routine Pap and HPV testing for women over the age of 30 to identify women most likely to develop cervical cancer.(2)

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications. For more information, visit www.hologic.com.

Forward Looking Statement Disclaimer

This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of the Cervista HPV tests. There can be no assurance that the tests will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the Cervista HPV tests can only be determined on a case-by-case basis depending on the particular circumstances of the test and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based. Certain factors that could adversely affect the Company's business and prospects are described in Hologic filings with the Securities and Exchange Commission.

Hologic, Cervista and ThinPrep are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries. Hybrid Capture® and hc2® are Qiagen trademarks.

(1) Cervista® HPV HR package insert, 2009

(2) ACOG Practice Bulletin 99, Obstet Gynecol. 2008;112:1419-1444

Media Contacts: Olga Karagiannis Anne Rivers Hologic, Inc. Hologic, Inc. Tel: 781.761.7069 Tel: 508.263.8765 olga.karagiannis@hologic.com anne.rivers@hologic.com

SOURCE Hologic, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Sinovac to Host Conference Call to Report 2009 Fou...
S
Tianyin Appoints Dr. James Jiayuan Tong as Chief F...